Literature DB >> 3410216

Maintenance of hepatic bile acid secretion rate during overnight fasting by bedtime bile acid administration.

A Lanzini1, D Facchinetti, T C Northfield.   

Abstract

We have tested the hypothesis that the greater clinical efficacy of bedtime administration of bile acid in gallstone dissolution is due to prevention of the reduction in hepatic bile acid secretion that normally accompanies overnight interruption of the enterohepatic circulation, thus also reducing the secretion of supersaturated hepatic bile. We measured the hepatic bile acid secretion rate by combining duodenal perfusion of a nonabsorbable recovery marker (polyethylene glycol) with continuous intravenous infusion of a hepatic bile marker (indocyanine green). We studied 6 subjects with gallstones before and during administration of ursodeoxycholic acid (UDCA, 675 mg) at bedtime. Duplicate pretreatment studies revealed good reproducibility. Mean values for hepatic bile acid secretion rate were uninfluenced by chronic UDCA administration before the acute bedtime dose, but during the 4-h period after acute administration of UDCA the total bile acids secreted increased by a mean value of 2.2 mmol (p less than 0.01). Before treatment, nine of the 78 hourly samples were secreted at a hepatic bile acid secretion rate of less than 5 mumol/kg.h in the 6 patients studied, compared with only one hourly sample during UDCA administration. Super-saturated hepatic bile was secreted for a mean of 9.5 h before treatment, and for 1.2 h during UDCA treatment (p less than 0.005). We conclude that if UDCA is administered at bedtime, this maintains the hepatic bile acid secretion rate overnight, thus reducing secretion of supersaturated hepatic bile, in addition to the well-established effect of UDCA on cholesterol secretion.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3410216     DOI: 10.1016/0016-5085(88)90179-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  6 in total

Review 1.  Targets for current pharmacologic therapy in cholesterol gallstone disease.

Authors:  Agostino Di Ciaula; David Q H Wang; Helen H Wang; Leonilde Bonfrate; Piero Portincasa
Journal:  Gastroenterol Clin North Am       Date:  2010-06       Impact factor: 3.806

2.  Gallstone dissolution with oral bile acid therapy. Importance of pretreatment CT scanning and reasons for nonresponse.

Authors:  S P Pereira; M J Veysey; C Kennedy; S H Hussaini; G M Murphy; R H Dowling
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

3.  Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans.

Authors:  F Lanzarotto; B Panarotto; R Sorbara; M Panteghini; F Pagani; S Sosta; A Lanzini
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

Review 4.  Pharmacological treatment of gallstones. Practical guidelines.

Authors:  A Lanzini; T C Northfield
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

5.  Therapy of gallstone disease: What it was, what it is, what it will be.

Authors:  Piero Portincasa; Agostino Di Ciaula; Leonilde Bonfrate; David Qh Wang
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-04-06

6.  Efficacy of Magnesium Trihydrate of Ursodeoxycholic Acid and Chenodeoxycholic Acid for Gallstone Dissolution: A Prospective Multicenter Trial.

Authors:  Jong Jin Hyun; Hong Sik Lee; Chang Duck Kim; Seok Ho Dong; Seung-Ok Lee; Ji Kon Ryu; Don Haeng Lee; Seok Jeong; Tae Nyeun Kim; Jin Lee; Dong Hee Koh; Eun Taek Park; In-Seok Lee; Byung Moo Yoo; Jin Hong Kim
Journal:  Gut Liver       Date:  2015-07       Impact factor: 4.519

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.